Financial Performance - The company's revenue for Q1 2023 was CNY 473,030,518.35, representing a 27.63% increase compared to CNY 370,629,245.42 in the same period last year[5] - Net profit attributable to shareholders for Q1 2023 was CNY 138,474,386.29, a significant increase of 171.11% from CNY 51,076,948.02 in the previous year[5] - The net profit after deducting non-recurring gains and losses was CNY 125,533,224.91, up 157.67% from CNY 48,718,416.30 year-on-year[5] - The basic earnings per share for Q1 2023 was CNY 0.3236, an increase of 171.02% compared to CNY 0.1194 in the same period last year[10] - Total operating revenue for Q1 2023 reached ¥473,030,518.35, an increase of 27.7% compared to ¥370,629,245.42 in Q1 2022[19] - Operating profit for Q1 2023 was ¥149,428,037.24, up 165.7% from ¥56,213,208.39 in the same period last year[19] - Net profit attributable to the parent company for Q1 2023 was ¥138,474,386.29, a significant increase from ¥51,076,948.02 in Q1 2022, representing a growth of 171.5%[20] - Basic earnings per share for Q1 2023 were ¥0.3236, compared to ¥0.1194 in Q1 2022, reflecting a 171.5% increase[20] Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 3,692,458,938.45, reflecting a 4.18% increase from CNY 3,544,216,145.59 at the end of the previous year[5] - The total current assets amounted to ¥2,633,566,082.40, up from ¥2,514,310,007.04, indicating an increase of about 4.7%[15] - The total assets of the company reached ¥3,692,458,938.45, compared to ¥3,544,216,145.59 at the beginning of the year, reflecting a growth of approximately 4.2%[16] - The total liabilities decreased to ¥762,787,304.45 from ¥804,413,526.41, a reduction of approximately 5.2%[17] - Total equity attributable to shareholders increased to ¥2,929,671,634.00 from ¥2,739,802,619.18, marking a growth of 6.9%[17] Cash Flow - The company's cash and cash equivalents at the end of Q1 2023 amounted to CNY 148,591,670.00, which is a 50.16% increase from CNY 98,957,000.00 year-on-year[10] - The net cash flow from operating activities for Q1 2023 was CNY 48,269,069.80, a decrease of 7.21% compared to CNY 52,021,509.15 in the same period last year[5] - Cash generated from operating activities was ¥509,891,004.68, compared to ¥459,218,493.82 in the previous year, indicating an increase of 11.1%[21] - The net cash flow from operating activities for Q1 2023 was ¥48,269,069.80, a decrease of 1.44% compared to ¥52,021,509.15 in Q1 2022[22] - The total cash and cash equivalents at the end of Q1 2023 reached ¥1,485,916,653.31, up from ¥989,579,920.30 at the end of Q1 2022, representing a significant increase of 50.3%[23] Expenses - The company experienced a 44.05% increase in selling expenses, totaling CNY 10,568,180.00, primarily due to increased human resources and travel costs[9] - The company’s financial expenses decreased by 464.05% to -CNY 730,460.00, mainly due to increased interest income[9] - Research and development expenses for Q1 2023 were ¥80,009,904.74, up from ¥75,702,238.74 in Q1 2022, reflecting a growth of 5.4%[19] - Sales expenses increased to ¥105,681,831.55 from ¥73,365,183.75, a rise of 43.9% year-over-year[19] - Cash paid for purchasing goods and services was ¥194,127,831.33, an increase of 22.47% compared to ¥158,565,395.48 in Q1 2022[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 13,518[11] - The largest shareholder, Chen Zhiqiang, holds 22.37% of the shares, totaling 95,725,200 shares, with 11,500,000 shares pledged[12] Other Information - The company reported a total of CNY 12,941,161.38 in non-recurring gains and losses for Q1 2023[6] - The company did not conduct an audit for the Q1 2023 report[24]

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2022, representing a year-on-year increase of 15% compared to 2021[13]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the year, representing a growth of 20% compared to the previous year[76]. - The company achieved a total revenue of 1,762.649 million yuan in 2022, representing a year-on-year growth of 22.02%[49]. - The revenue from the ultrasound product line was ¥1,079,527,925.32, accounting for 61.24% of total revenue, with a growth of 14.14% from ¥945,800,908.14 in 2021[56]. - The revenue from endoscopes and related treatment instruments increased by 42.98% to ¥611,598,329.82, representing 34.70% of total revenue[56]. - The company reported a net profit of 300 million RMB for 2022, reflecting a growth of 20% compared to the previous year[13]. - Net profit attributable to shareholders for 2022 was ¥369,811,713.74, a 49.57% increase from ¥247,244,612.13 in 2021[19]. - The gross profit margin for 2022 was 45%, which is a slight improvement from 43% in the previous year[13]. - The company reported a gross margin of 60%, maintaining a stable margin despite rising raw material costs[76]. - The company reported a significant increase in trading financial assets to CNY 419.45 million, accounting for 11.83% of total assets, due to increased purchases of financial products[92]. Research and Development - The company's R&D expenses accounted for approximately 20% of its operating revenue in recent years, indicating a strong commitment to innovation despite inherent risks in product development[2]. - The company invested in R&D with expenditures of CNY 237.42 million, CNY 263.06 million, and CNY 328.96 million for the years 2020, 2021, and 2022, respectively, representing 20.41%, 18.21%, and 18.66% of total revenue[41]. - The company has a dedicated R&D team of 631 personnel, accounting for 27.04% of total employees, ensuring a strong focus on product development[43]. - The company has developed advanced ultrasound technologies, including high-frequency probe technology and AI image recognition, positioning itself as a leader in the ultrasound field[40]. - The company launched the world's first AI-based dynamic image technology for prenatal ultrasound screening, enhancing efficiency in obstetric examinations[30]. - The company is focusing on improving customer service and support processes, which has led to increased customer satisfaction and repeat purchases[48]. - The company is committed to ongoing research and development to maintain its competitive edge in the medical technology sector[79]. Market Expansion - The company is expanding its market presence in Europe, with plans to establish a new distribution center in Germany by mid-2023[13]. - The company is actively pursuing market expansion and product innovation to enhance its competitive position in the medical device sector[67]. - The company is expanding its market presence in Southeast Asia, with plans to enter three new countries by the end of 2023[112]. - The company has established a global marketing network covering nearly 130 countries and regions, enhancing its brand promotion and distributor training capabilities[43]. - The company is committed to localizing its operations in developed markets while refining its approach in developing markets, resulting in rapid business growth in regions like the US, Germany, and India[53]. Product Development - The company plans to launch three new ultrasound products in 2023, aiming to capture a larger market share in the medical imaging sector[13]. - The company has launched new products, including the P12 Elite and P20 Elite series ultrasound diagnostic systems, which were registered on September 15 and September 13, 2022, respectively[84]. - The company has introduced several new products in the endoscope field, including ultra-thin electronic gastroscopes and electronic colonoscopes, significantly enriching its product offerings and supporting market penetration[50]. - The company has launched the ProPet series of veterinary ultrasound products in 2022, expanding its market reach in ultrasound applications[35]. - The company has developed a unique competitive advantage in the hard endoscope field by integrating hard endoscopes with ultrasound systems[32]. Regulatory Compliance - The company is subject to significant regulatory risks due to the medical device industry's heavy government oversight, which could impact pricing and market dynamics[5]. - The company has received multiple certifications, including NMPA, FDA, and CE, ensuring compliance with international quality standards for its medical devices[44]. - The company has maintained compliance with internal control standards, ensuring the accuracy and completeness of financial reporting[160]. - The company has not reported any violations regarding external guarantees during the reporting period[171]. Corporate Governance - The board of directors held five meetings during the reporting period to ensure effective governance and decision-making[113]. - The company has established a comprehensive performance evaluation and incentive mechanism for its directors, supervisors, and senior management, ensuring competitive compensation[119]. - The company has a robust governance structure with independent directors who bring diverse expertise, including legal and engineering backgrounds[131]. - The company is committed to protecting the legal rights of shareholders through effective governance practices[142]. Financial Management - The company reported a total cash outflow from operating activities of CNY 1,663,498,449.80, which is a 16.82% increase from CNY 1,423,986,369.23 in the previous year[88]. - The net cash flow from operating activities reached ¥473,255,552.95, up 56.20% from ¥302,989,915.92 in 2021[19]. - The total amount of funds raised in 2021 was CNY 769,055,967.35 after deducting issuance costs, with no funds utilized as of the reporting period[100]. - The company has committed to invest CNY 24,705.43 million in the development of color ultrasound and endoscope products, with a cumulative investment of CNY 24,321.31 million, achieving 100.46% of the planned progress[102]. Strategic Initiatives - The company plans to implement a new marketing strategy aimed at increasing brand awareness, with a budget allocation of 100 million RMB for 2023[112]. - The company is exploring potential acquisitions to enhance its product portfolio, focusing on companies specializing in diagnostic imaging technologies[76]. - The company completed a strategic acquisition of a smaller biotech firm for 500 million RMB to enhance its product portfolio[112]. - The company has implemented a training program focused on team capability development, emphasizing a "people-oriented, technology innovation" philosophy[150].

关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳开立生物医疗科技股份有限公司（以下简称"公司"）定于 2023 年 4 月 18 日（星期二）下午 15:00-17:00 在全景网举办 2022 年度网上业绩说明会， 本次年度业绩说明会将采用网络远程的方式举行，投资者可登录全景网"投资 者关系互动平台"（http://ir.p5w.net）参与互动交流。 出席本次年度网上业绩说明会的人员包括：公司董事长陈志强先生、董事 会秘书李浩先生、财务总监罗曰佐先生、独立董事华小宁先生、保荐代表人郭 小元先生。 证券代码：300633 证券简称：开立医疗 公告编号：2023-015 深圳开立生物医疗科技股份有限公司 为做好中小投资者保护工作，增进投资者对公司的了解和认同，以提升公 司治理水平和企业整体价值，现就公司 2022 年度网上业绩说明会提前向投资者 征集相关问题，投资者可于 2023 年 4 月 17 日（星期一）17:00 前将有关问题通 过电子邮件的形式发送至公司投资者关系互动邮箱：ir@sonoscape.n ...

Group 1: Revenue Expectations - The company expects steady growth in revenue across various product lines, including ultrasound, soft endoscopes, hard endoscopes, consumables, and intravascular ultrasound (IVUS) [2][3] - Ultrasound products are anticipated to exceed industry average growth due to the company's leading technology and comprehensive product range [2] - The soft endoscope market is growing rapidly, with increasing recognition in tertiary hospitals, and the company expects continued high growth in this segment [2] Group 2: Profitability and Costs - The company has not provided specific guidance on net profit but expects a gradual increase in net profit margin as revenue grows and gross margins stabilize [3] - Sales and R&D expenses are relatively high, primarily due to personnel costs, but are expected to remain stable in 2023 without significant personnel expansion [3] Group 3: Impact of Subsidized Loans - The company believes that the impact of subsidized loan policies on its business is minimal due to factors such as the lengthy procurement process for medical equipment and the cautious approach of hospitals regarding cash flow [3] Group 4: Product Development and Market Strategy - The hard endoscope business saw a doubling in revenue in 2022, with strong competitive advantages from new 2K and 4K products [3] - The company plans to maintain a balance between investment in new product lines and overall company performance to ensure healthy development [4] - The intravascular ultrasound products are expected to start generating orders in 2023, with a growing market presence in PCI surgeries [3]

Group 1: Company Overview - Shenzhen Kaili Biomedical Technology Co., Ltd. provides a comprehensive introduction to its history, qualifications, product lines, employee situation, sales performance, and strategic direction [3] - The company reported a market share of approximately 20% in top-tier hospitals, up from less than 10% the previous year, driven by high-end products like the S50 [3][4] Group 2: Product and Market Insights - The domestic market's leading brands in ultrasound are Mindray and Kaili, with significant gaps between them and other manufacturers [4] - The company anticipates that high-end product launches will impact low-end product prices by around 10%, but older products are being upgraded or phased out rather than competing on price [4][5] - The lifespan of ultrasound products is generally around 10 years, with top-tier hospitals typically using them for about 3 years [5] Group 3: Financial Projections - The domestic endoscope market was valued at approximately 6 billion yuan last year, with the company aiming for a revenue of 600 million yuan in four years, representing a 10% market share [7][8] Group 4: Sales and Distribution - The company employs different teams for ultrasound and endoscope sales, although their sales models and experiences are interconnected [7] - The sales cycle from order confirmation to revenue recognition typically takes about half a month [8] Group 5: Competitive Landscape - The medical industry has high technical and registration barriers, making it challenging for new entrants to compete effectively [7] - The company does not foresee significant impacts from the two-invoice system on sales in the near term, as medical devices require after-sales service and on-site guidance [6]

Financial Performance - As of December 31, 2016, the company's total liabilities amounted to 296.44 million CNY, with a debt-to-asset ratio of 29.16% and interest expenses of 3.36 million CNY for the year [3] - In Q1 2017, the company achieved operating revenue of 159.82 million CNY, representing a year-on-year growth of 68.70%, and a net profit attributable to shareholders of 10.06 million CNY, up 58.31% [4][11] - For the full year 2016, the company reported operating revenue of 719.36 million CNY, a growth of 4.89%, with a total profit of 140.53 million CNY, increasing by 18.68%, and a net profit of 130.42 million CNY, up 23.19% [12][13] Strategic Plans - The company plans to enhance market promotion and investment in the endoscope sector over the next three years, with no current acquisition plans [4][11] - Future goals include expanding product lines and strengthening competitiveness in overseas markets, particularly for high-end products [6][8] Market Outlook - The global medical device market is expected to reach 529.8 billion USD by 2022, with China's market growing from 120 billion CNY in 2010 to 308 billion CNY in 2015 [8] - The company is focused on the medical device sector, which is a key area supported by national policies, indicating a broad development outlook [8] Core Competencies - The company's core competitive advantages lie in R&D capabilities, product quality, marketing networks, and talent [5] - The company respects its competitors and aims to maintain a leading position in the ultrasound market, having launched China's first high-definition digestive endoscope in 2016 [7][11] Government Support - The company benefits from various government subsidies and tax incentives, including a 10% corporate income tax rate for key software enterprises and VAT refunds for certain products [5]

Group 1: Market Position and Product Development - The company views the import substitution in the medical device sector as an ongoing process, dependent on the quality and performance of domestic brands reaching the same level as imported products [3] - Domestic ultrasound products have accelerated import substitution recently, particularly after the introduction of high-end color ultrasound machines [3] - The company’s high-definition endoscopes are competitive with some Japanese products, indicating a faster import substitution process compared to ultrasound [3] Group 2: Government Support and Industry Trends - National policies are expected to support the self-sufficiency of high-end medical devices, with funding for early-stage R&D and later sales and procurement policy support [3] - Recent government initiatives to enhance medical infrastructure, such as the addition of new tertiary hospitals and increased ICU bed numbers, are likely to boost future equipment procurement demand [5] Group 3: Supply Chain and Sales Strategy - The company primarily sources electronic components from abroad, with no current restrictions on procurement, while key structural components are designed and controlled in-house [4] - High-end medical devices are marketed through academic promotion, with industry experts demonstrating products at forums and online teaching sessions [4] - The sales strategy focuses on establishing demonstration windows in over 100 tertiary hospitals, primarily targeting secondary and lower-tier hospitals [4] Group 4: Product Lifecycle and Revenue Model - Endoscope equipment has a long usage period, with a renewal cycle of approximately 3 to 4 years, differing from other medical devices [5] - The pricing model for the company’s system is designed to generate significant revenue from high-end consumables when endoscope replacements are needed after three years [5]